Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538938 | 1.00 | KCNMA1 (0.38) | KCNMA1KDM4ECTSAHCRTR1L3MBTL1 | |
| SCHEMBL2538940 | 1.00 | KCNMA1 (0.38) | KCNMA1KDM4ECTSAHCRTR1L3MBTL1 | |
| SCHEMBL2538932 | 1.00 | KCNMA1 (0.38) | KCNMA1KDM4ECTSAHCRTR1L3MBTL1 | |
| SCHEMBL2583774 | 1.00 | KCNMA1 (0.38) | KCNMA1KDM4ECTSAHCRTR1L3MBTL1 | |
| SCHEMBL2538915 | 0.84 | SLC18A3 (0.41) | KCNMA1KDM4ECTSAL3MBTL1ALDH1A1 | |
| SCHEMBL2538913 | 0.84 | SLC18A3 (0.41) | KCNMA1KDM4ECTSAL3MBTL1ALDH1A1 | |
| SCHEMBL2594258 | 0.79 | ALDH1A1 (0.41) | KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL2594252 | 0.79 | ALDH1A1 (0.41) | KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL2594255 | 0.79 | ALDH1A1 (0.41) | KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL2594251 | 0.79 | ALDH1A1 (0.41) | KDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571879-B1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-8481528-B2 | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2571879-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011134877-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263573-A1 | HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1B, AVPR1A, AVPR2 | KCNMA1 427/4885KDM4E 4245/4885CTSA 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.